Acrivon Therapeutics
ACRV
48 hedge funds and large institutions have $32.7M invested in Acrivon Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 11 closing their positions.
1.07% less ownership
Funds ownership: 56.78% → 55.71% (-1.1%)
9% less funds holding
Funds holding: 53 → 48 (-5)
11% less capital inflows, than outflows
Capital inflows: $1.84M | Capital outflows: $2.08M
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$960K |
| 2 |
Two Sigma Investments
New York
|
+$194K |
| 3 |
Renaissance Technologies
New York
|
+$160K |
| 4 |
Two Sigma Advisers
New York
|
+$146K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$129K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$498K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$455K |
| 3 |
HRT Financial
New York
|
-$173K |
| 4 |
Goldman Sachs
New York
|
-$169K |
| 5 |
Millennium Management
New York
|
-$156K |
ACRV Hedge Fund Activity: Q3 2025 in Review
48 of the 7,653 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q3 2025, worth a combined $32.7M — up 54% from $21.2M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ACRV and 6 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 11 added.
The largest buyer was UBS Group, adding an estimated $960K. The largest seller was Citadel Advisors, cutting an estimated $498K.
- 48 institutional investors held Acrivon Therapeutics (ACRV) as of Q3 2025, down from 53 in Q2 2025.
- Funds reported $32.7M of Acrivon Therapeutics stock for Q3 2025, up 54% quarter-over-quarter.
- 6 funds opened new Acrivon Therapeutics positions in Q3 2025 and 11 closed out, a net change of -5 holders.
- The largest Acrivon Therapeutics buyer in Q3 2025 was UBS Group, an estimated $960K added.
- The largest Acrivon Therapeutics seller in Q3 2025 was Citadel Advisors, an estimated $498K sold.
Based on aggregated 13F filings for Q3 2025.